Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma
      QxMD      Google Scholar   
Citation:
Neuro-oncology vol 20 (9) 1240-50
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
7
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
Roche/Genentech  
Grants:
RSG-15-003-01-CCE, U10CA180821  
Corr. Author:
 
Authors:
                                                                 
Networks:
11030, CA006, CA824, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-UT003, NC002   
Study
Alliance-A151620
Multiple Studies, or Legacy Studies in Alliance Study:
NCCTG-N0874
Phases:
N/A, 1/2
Keywords: